Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways-Reference-Cited by-同舟云学术

Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways

Published:2009 Issue:1 Volume:8 Page:118
ISSN:1476-4598
Container-title:Molecular Cancer
language:en
Short-container-title:Molecular Cancer

Author:

Pignochino Ymera,Grignani Giovanni,Cavalloni Giuliana,Motta Manuela,Tapparo Marta,Bruno Stefania,Bottos Alessia,Gammaitoni Loretta,Migliardi Giorgia,Camussi Giovanni,Alberghini Marco,Torchio Bruno,Ferrari Stefano,Bussolino Federico,Fagioli Franca,Picci Piero,Aglietta Massimo

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Molecular Medicine

Cited by 162 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting the EphA2 pathway: could it be the way for bone sarcomas?;Cell Communication and Signaling;2024-09-09

2. Targeted anti-angiogenesis therapy for advanced osteosarcoma;Frontiers in Oncology;2024-08-26

3. Mefenamic acid exhibits antitumor activity against osteosarcoma by impeding cell growth and prompting apoptosis in human osteosarcoma cells and xenograft mice model;Chemico-Biological Interactions;2024-04

4. In vitro cytotoxicity of magnetic-fluorescent bioactive glasses on SaOS-2, MC3T3-E1, BJ fibroblast cells, their hemolytic activity, and sorafenib release behavior;Biomaterials Advances;2024-04

5. Ezrin's role in gastric cancer progression: Implications for immune microenvironment modulation and therapeutic potential;Heliyon;2024-03